Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.

Yohei Doi Takayuki HamanoSatoshi YamaguchiYusuke Sakaguchi Jun-Ya Kaimori Yoshitaka Isaka

Published in: Diabetes, obesity & metabolism (2023)

The renoprotective effects of canagliflozin in patients at a high risk of ESKD can be significantly explained by changes in RBC variables and UACR. The complementary mediating effects of RBC variables and UACR may support the renoprotective effect of canagliflozin in different patient groups.

Keyphrases

case report
clinical trial
study protocol
diabetic nephropathy
phase ii